You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Grassroots efforts are leading the way in a number of commercial and non-commercial screening tests in development.
NEB plans to expand its product lines into new areas of research including genome editing, the companies said.
Last week's SynBioBeta conference was indicative of the high degree of interest in the synthetic bio space from omics research tool vendors.
This week's news includes Adaptive Biotechnologies, Thermo Fisher Scientific, TATAA Biocenter, and New England Biolabs.
The new partnership will support the analysis of glycans in 30,000 human samples by the end of 2021.
New England Biolabs is using Avacta's affimers with a development-stage research and diagnostic assay that could launch as early as next year.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.
A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.
NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.
In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.